Professor Richard Scolyer’s Pioneering Role in Brain Cancer Immunotherapy and His Death in 2026

Key Facts

• Professor Richard Scolyer died on 7 June 2026 at age 59.
• He was diagnosed with Grade 4 glioblastoma, an aggressive and incurable brain tumour, in May 2023.
• Scolyer received an experimental treatment involving combination immunotherapy consisting of multiple checkpoint inhibitors given before surgery, followed by tumor removal and a personalised peptide vaccine.
• He and Professor Georgina Long jointly received the 2024 Australian of the Year award for their groundbreaking work in melanoma immunotherapy.
• The treatment approach was world-first and notably risky, as delaying surgery in glioblastoma can carry significant risks.
• Following his case, a clinical trial based on his treatment was launched at Duke University to evaluate its efficacy in glioblastoma more broadly.
• The Australian Prime Minister Anthony Albanese announced a state funeral to honour his contributions.

Background & Context

Glioblastoma is classified as a grade 4 glioma by the World Health Organization and is the most aggressive and common malignant brain tumor with a median survival typically 12–18 months after diagnosis. Its treatment has historically involved surgery, radiation, and chemotherapy but has not substantially changed for nearly two decades. Prof Richard Scolyer was an internationally recognized pathologist and melanoma researcher who, following his devastating glioblastoma diagnosis, volunteered for a novel, high-risk immunotherapy protocol combining lessons from melanoma therapy advancements.

This protocol entailed administering three different immune checkpoint inhibitors simultaneously before surgery to activate the immune system against tumor cells, followed shortly by tumor resection, radiation therapy, additional checkpoint blockade, and a personalized peptide vaccine designed to enhance immune recognition of tumor-specific antigens. Despite risks of immunotherapy toxicity and potential brain swelling, the treatment represented a major breakthrough.

Why This Matters for Exams / Exam Relevance

• Illustrates recent translational research advances in oncology bridging immunotherapy and neuro-oncology.
• Highlights the challenges and potential of personalized medicine and experimental treatments in fatal cancers.
• Shows the importance of interdisciplinary collaboration between pathology, oncology, clinical trials, and patient advocacy.
• Dates and events: Diagnosis May 2023, Australian of the Year 2024, Death June 2026, clinical trial launch.
• Key figures and institutions: Prof Richard Scolyer, Prof Georgina Long, Melanoma Institute Australia, Duke University, Australian Government.

Points to Remember

• Richard Scolyer was a leading pathologist and melanoma immunotherapy researcher from Australia.
• Diagnosed with aggressive grade 4 glioblastoma in May 2023, prognosis expected 6–8 months initially.
• Underwent a world-first, high-risk immunotherapy treatment involving checkpoint inhibitors pre-surgery, followed by surgery and personalized vaccine.
• Joint Australian of the Year 2024 with Georgina Long for melanoma immunotherapy breakthroughs.
• His case led to a clinical trial at Duke University aiming to replicate and study treatment outcomes.
• Death on 7 June 2026 was widely mourned and marked by an official state funeral.